Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 4 N=27 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation
Hyperglycemia
Primary: Time to Achieve Glycemic Control — 225 Minutes
N/A N=80 Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease
Diabetes · Kidney Diseases
Primary: Mean Glucose Concentration Measured by CGM — 151.5 mg/dL
N/A N=101 The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes
Diabetes Mellitus, Type 2 · Medication Adherence · HYPERGLYCEMIA
Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin
Phase 4 N=164 Study of Glycemic Control on Liver Transplantation Outcomes
Evidence of Liver Transplantation · Hyperglycemia · Rejection
Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709
N/A N=37 The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery
Diabetes · Hyperglycemia · Surgical Site Infection
Primary: Number of Participants Undergoing Open Heart Surgery With Postoperative Surgical Site Infection — 4; 5; 5 participants — p=0.512
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=156 Glucose Control Using 1,5-AG Testing
Diabetes
Primary: Diagnosis-Treatment — 31.7; 35.0; 29.1; 31.9 CPV diagnosis-treatment percentage score
N/A N=177 New Ways to Help Patients Improve Their Diabetes Control
Diabetes Mellitus
Primary: Change in Percent of Glycosylated Hemoglobin 6 Months Following Enrollment — -0.74; -0.55; -0.89 Percent of glycosylated hemoglobin
N/A N=7 Continuous Glucose Monitoring to Measure Effect of Glycemic Index
Type 1 Diabetes Mellitus
Primary: Mean Area Under the Curve for Rise in Breakfast Post-prandial. — 61; 583 min x (mmol/l)
N/A N=31 Effect of Inpatient Diabetes Management on Outpatient Glycemic Control
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1c — -1.3; -0.4 HbA1c, %
N/A N=30 Glycemic Optimization On Discharge From the Emergency Room
Diabetes Mellitus
Primary: Change in Diabetes Distress — 0; 0.5 units on a scale
N/A N=106 The Role of Apathy in Glycemic Control
Apathy · Diabetes
Primary: Change in HbA1c Over Baseline — -1.0; -0.1 percentage of HbA1c
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
Phase 4 N=33 Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes
Type 2 Diabetes · Inpatient
Primary: Difference Between Heart Rate Variability Between Intravenous and Subcutaneous Group — 1.0; 2.6 none (ratio) — p=0.05
Phase 3 N=12 New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Type 1 Diabetes
Primary: The Area Under the Curve (AUC) of Plasma Glucose (PG) Concentrations During the 5-hour Postprandial Period (AUC-PG0-5 h). — 724.6; 668.8 mg*h/dl
Phase 3 N=2,684 Computerized Glucose Control in Critically Ill Patients
Hyperglycemia · Critical Illness
Primary: All-cause 90-day Mortality — 431; 447 participants
Phase 4 N=23 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Non-Insulin-Dependent Diabetes Mellitus
Primary: Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment — 17.31; 17.53; 15.30; 10.83 Hours — p=0.064
N/A N=200 Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: The Achievement Rate of HbA1c (<7%) — 63; 65; 58; 64 Participants — p=0.9917
N/A N=89 SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD
Diabetes Mellitus, Type 2 · Coronary Artery Disease
Primary: Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS) — 8.86; 8.72; 8.80; 6.87 mmol/L
N/A N=3 Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
Chronic Kidney Diseases · Type 2 Diabetes
Primary: Glucose Time in Range — 495.2; 573.3 minutes per day
N/A N=157 Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
N/A N=115 Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Type 1 Diabetes
Primary: Difference in HbA1C From Baseline and 6 Months — -0.57; -0.81 percentage of HbA1C
N/A N=85 Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients
Hyperglycemia · Hypoglycemia · Critical Illness
Primary: Time in Target Blood Glucose Range (BG 70-180mg/dL) — 60.5; 61.4 percentage of time within target range
N/A N=151 Comparative Trial Between 3 Types of Insulin Infusion Protocols
Hyperglycemia
Primary: Differences in Glycemic Control as Measured by Time Reach Glycemic Control for Each Treatment Group. — 5; 10.1; 7.7 Time to reach glycemic control in hours — p=<0.05
N/A N=235 Point-of-Care Glucose Testing and Insulin Supplementation
Diabetes
Primary: Mean Fasting Blood Glucose — 162; 157 mg/dL
N/A N=16 Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.
Diabetes Mellitus
Primary: Percentage of Time Spent in Hyperglycemia > 180 mg/dL — 35.47; 35.25 percentage of time spent > 180mg/dL
N/A N=472 CGM Precision and Glycaemic Variability
Diabetes Type 1
Primary: Optimal Time Shift of Continuous Glucose Monitoring Measurements — 1.01 Percentage point change in MARD